EP Wealth Advisors LLC Has $4.52 Million Position in Gilead Sciences, Inc. (NASDAQ:GILD)

EP Wealth Advisors LLC increased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 13.7% during the third quarter, Holdings Channel reports. The institutional investor owned 53,951 shares of the biopharmaceutical company’s stock after purchasing an additional 6,492 shares during the quarter. EP Wealth Advisors LLC’s holdings in Gilead Sciences were worth $4,523,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Lantz Financial LLC raised its stake in shares of Gilead Sciences by 3.5% in the second quarter. Lantz Financial LLC now owns 24,920 shares of the biopharmaceutical company’s stock valued at $1,710,000 after purchasing an additional 840 shares in the last quarter. Cooper Financial Group lifted its holdings in shares of Gilead Sciences by 162.5% during the 2nd quarter. Cooper Financial Group now owns 7,209 shares of the biopharmaceutical company’s stock worth $495,000 after acquiring an additional 4,463 shares during the period. M&G Plc boosted its position in shares of Gilead Sciences by 59.5% during the 2nd quarter. M&G Plc now owns 154,717 shares of the biopharmaceutical company’s stock valued at $10,675,000 after acquiring an additional 57,709 shares in the last quarter. Gemmer Asset Management LLC bought a new stake in Gilead Sciences in the second quarter valued at about $270,000. Finally, Diversified Trust Co raised its position in Gilead Sciences by 11.8% in the second quarter. Diversified Trust Co now owns 32,987 shares of the biopharmaceutical company’s stock worth $2,263,000 after purchasing an additional 3,483 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors.

Insider Activity at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 248,645 shares of the company’s stock in a transaction that occurred on Friday, November 29th. The shares were sold at an average price of $92.76, for a total value of $23,064,310.20. Following the completion of the sale, the chief financial officer now owns 138,919 shares of the company’s stock, valued at approximately $12,886,126.44. This represents a 64.16 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Merdad Parsey sold 164,211 shares of Gilead Sciences stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $91.92, for a total transaction of $15,094,275.12. Following the transaction, the insider now directly owns 80,801 shares in the company, valued at approximately $7,427,227.92. This represents a 67.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 476,591 shares of company stock worth $43,747,615 in the last ninety days. Company insiders own 0.16% of the company’s stock.

Analyst Ratings Changes

GILD has been the topic of several analyst reports. JPMorgan Chase & Co. upped their price objective on Gilead Sciences from $100.00 to $105.00 and gave the company an “overweight” rating in a research note on Thursday, November 7th. UBS Group upped their price target on Gilead Sciences from $70.00 to $96.00 and gave the company a “neutral” rating in a research report on Thursday, November 21st. Leerink Partners raised Gilead Sciences from a “market perform” rating to an “outperform” rating and lifted their price objective for the company from $74.00 to $96.00 in a report on Monday, October 21st. Maxim Group lowered shares of Gilead Sciences from a “buy” rating to a “hold” rating in a report on Friday, November 8th. Finally, Barclays lifted their price target on shares of Gilead Sciences from $84.00 to $95.00 and gave the company an “equal weight” rating in a report on Thursday, November 7th. Twelve investment analysts have rated the stock with a hold rating, eleven have given a buy rating and four have given a strong buy rating to the stock. According to data from MarketBeat.com, Gilead Sciences presently has a consensus rating of “Moderate Buy” and a consensus target price of $95.41.

Gilead Sciences Trading Down 1.3 %

Shares of NASDAQ GILD opened at $92.13 on Monday. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $98.90. The firm has a market capitalization of $114.82 billion, a P/E ratio of 1,023.67, a P/E/G ratio of 2.84 and a beta of 0.18. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.26 and a quick ratio of 1.10. The company’s 50 day simple moving average is $89.20 and its 200 day simple moving average is $78.72.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, beating analysts’ consensus estimates of $1.58 by $0.44. The company had revenue of $7.55 billion for the quarter, compared to the consensus estimate of $7.01 billion. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The firm’s quarterly revenue was up 7.0% on a year-over-year basis. During the same quarter in the prior year, the business posted $2.29 EPS. On average, analysts predict that Gilead Sciences, Inc. will post 4.37 EPS for the current year.

Gilead Sciences Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, December 30th. Stockholders of record on Friday, December 13th will be paid a $0.77 dividend. The ex-dividend date of this dividend is Friday, December 13th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 3.34%. Gilead Sciences’s dividend payout ratio (DPR) is presently 3,422.22%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.